摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Ethyl 2-Amino-4-(methoxymethyl)thiazole-5-carboxylate | 905807-82-1

中文名称
——
中文别名
——
英文名称
Ethyl 2-Amino-4-(methoxymethyl)thiazole-5-carboxylate
英文别名
ethyl 2-amino-4-(methoxymethyl)-1,3-thiazole-5-carboxylate
Ethyl 2-Amino-4-(methoxymethyl)thiazole-5-carboxylate化学式
CAS
905807-82-1
化学式
C8H12N2O3S
mdl
——
分子量
216.261
InChiKey
SSPWUMHZSKIWSU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    361.8±32.0 °C(Predicted)
  • 密度:
    1.287±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    14
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    103
  • 氢给体数:
    1
  • 氢受体数:
    6

安全信息

  • 危险等级:
    IRRITANT

反应信息

  • 作为反应物:
    描述:
    Ethyl 2-Amino-4-(methoxymethyl)thiazole-5-carboxylate 在 t-butyl nitrite 、 copper dichloride 作用下, 以 乙腈 为溶剂, 反应 2.0h, 以95%的产率得到ethyl 2-chloro-4-(methoxymethyl)thiazole-5-carboxylate
    参考文献:
    名称:
    Optimization of Pyrrolamide Topoisomerase II Inhibitors Toward Identification of an Antibacterial Clinical Candidate (AZD5099)
    摘要:
    AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. It was derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting the ATP binding site of bacterial type II topoisomerases. The program described herein varied a 3-piperidine substituent and incorporated 4-thiazole substituents that form a seven-membered ring intramolecular hydrogen bond with a 5-position carboxylic acid. Improved antibacterial activity and lower in vivo clearances were achieved. The lower clearances were attributed, in part, to reduced recognition by the multidrug resistant transporter Mrp2. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Hence, 63 could offer a novel treatment for serious issues of resistance to currently used antibacterials.
    DOI:
    10.1021/jm500462x
点击查看最新优质反应信息